Mind Medicine (Mind Medicine) Debt-to-Equity : 0.07 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine Debt-to-Equity?

Mind Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Mind Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $14.19 Mil. Mind Medicine's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $196.06 Mil. Mind Medicine's debt to equity for the quarter that ended in Mar. 2024 was 0.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Mind Medicine's Debt-to-Equity or its related term are showing as below:

MNMD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.04 Max: 0.18
Current: 0.07

During the past 4 years, the highest Debt-to-Equity Ratio of Mind Medicine was 0.18. The lowest was 0.00. And the median was 0.04.

MNMD's Debt-to-Equity is ranked better than
65.64% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs MNMD: 0.07

Mind Medicine Debt-to-Equity Historical Data

The historical data trend for Mind Medicine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine Debt-to-Equity Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.18

Mind Medicine Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial													-	-	0.15	0.18	0.07

Competitive Comparison of Mind Medicine's Debt-to-Equity

For the Biotechnology subindustry, Mind Medicine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mind Medicine's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mind Medicine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Mind Medicine's Debt-to-Equity falls into.

Mind Medicine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Mind Medicine's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	14.129)	/	78.134
	=	0.18

Mind Medicine's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	14.19)	/	196.059
	=	0.07

Mind Medicine (NAS:MNMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Mind Medicine Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Mind Medicine's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine (Mind Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (NAS:MNMD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MMQ:Germany MMED:Canada

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies.

Executives

Schond L. Greenway	officer: Chief Financial Officer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
Robert Barrow	director, officer: Chief Executive Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Dan Karlin	officer: Chief Medical Officer	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Carol A Vallone	director	490 SUMMER STREET, MANCHESTER MA 01944
Andreas Krebs	director	5 GIRALDA FARMS, MADISON NJ 07940
Mark Sullivan	officer: Chief Legal Officer	1000 BISHOPS GATE BOULEVARD, SUITE 300, MOUNT LAUREL NJ 08054
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Roger Crystal	director	445 PARK AVE, 10TH FL., NEW YORK NY 10022
Cynthia W. Hu	officer: Chief Legal Officer&Secretary	6440 WINDERMERE, NORTH BETHESDA MD 20852
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Sarah Y Vinson	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Stephen L Hurst	director	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Miri Halperin Wernli	director, officer: Executive President	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007
Carrie Liao	officer: VP, Controller&Acct Principal	C/O MIND MEDICINE INC., ONE WORLD TRADE CENTER, SUITE 8500, NEW YORK NY 10007